We herein report a case of Penicillium marneffei infection (PMI) in a Japanese man who was infected with human immunodeficiency virus-1 (HIV-1), who was diagnosed on the basis of a bone marrow culture and who was effectively treated with itraconazole. Our review of the PMI cases reported in Japan suggests that increased serum (1 3)-β-D-glucan levels are a useful diagnostic tool in cases of suspected PMI.
Introduction
Penicillium marneffei is a dimorphic fungus which is endemic to South and Southeast Asia. P. marneffei infection (PMI) is a prominent cause of morbidity and mortality among immunocompromised patients, particularly those infected with human immunodeficiency virus-1 (HIV-1) (1, 2). In Japan, only ten cases, all of which had a history of travel to endemic countries, have been reported thus far. We herein report one PMI case, provide a review of all of the PMI cases reported in Japan and investigate the usefulness of the detection of serum (1 3)-β-D-glucan (BDG) elevation in the diagnosis of PMI in nonendemic countries.
Case Report
A 66-year-old Japanese man who had lived in Vietnam for 40 years presented to a hospital with a 5-month history of diarrhea, a 1-month history of oral erosion, a 20-day history of heartburn, and weight loss (8 kg) . The patient had a history of herpes zoster infection eight years before admission. He was heterosexual and had no contact with animals. The patient was referred to our clinic under the suspicion of HIV infection and oral candidiasis.
The patient's vital signs were within the normal limits during the initial examination. A physical examination revealed oral thrush, a swollen left cervical lymph node (diameter: 1.5 cm), and tenderness in the left upper abdominal quadrant. Trunk computed tomography (CT) showed mild splenomegaly and multiple enlarged lymph nodes at the hepatic hilum and peritoneum. Laboratory tests revealed a decreased white blood cell count (3,000/mm 3 ), lymphopenia (4%), normal hemoglobin levels, elevated C-reactive protein levels (11.5 mg/dL, normal: <0.5 mg/dL), a decreased CD4 count (72/mm 3 ), a high plasma HIV-1 RNA level (69,000 copies/mL), and elevated (1 3)-β-D-glucan levels [336.8 pg/mL (normal: <20 pg/mL); Fungitec G test MK, Seikagaku Biobusiness, Tokyo, Japan] ( Table 1 ). The patient was diagnosed with HIV/acquired immunodeficiency syndrome (AIDS) and esophageal candidiasis and was prescribed fluconazole (200 mg/day). Colonoscopy revealed multiple aphthoid lesions from the cecum to the rectum with nonspecific pathological findings. A bone marrow culture with a mycobacterial bottle aspirated on day 11 revealed P. marneffei; based on this finding, the patient was treated for PMI by switching from fluconazole to itraconazole (400 mg/day) ( Figure) . The patient's symptoms improved and a trunk CT taken two weeks after the initiation of itraconazole treatment confirmed the shrinkage of the patient's abdominal lymph nodes. Eight weeks later, the itraconazole dose was decreased to 200 mg/day, and the patient was started on antiretroviral therapy (ART). Two years after ART initiation, his CD4 + cell counts increased to above 100/mm 3 and itra- Table 1 . Labolaory Findings at First Presentation.
conazole maintenance therapy was discontinued. There has been no recurrence of PMI over a follow-up period of 3 years in duration.
Discussion
PMI is a common, opportunistic, and sometimes fatal, fungal infection among HIV-infected patients in Southeast Asia (1); however, it is rare in other regions, including Japan. Clinical symptoms of PMI are nonspecific and include fever, anorexia, and gastrointestinal symptoms. The most common blood abnormalities are anemia, thrombocytopenia, and transaminase elevation (2) . A diagnosis of PMI is usually made by detecting the fungi in cultures of blood or other clinical specimens or by the histopathological demonstration of the organism in biopsy material. Cases that lack specific skin lesions (e.g., umbilicated papules) may be difficult to diagnose in nonendemic areas. Our patient did not have any typical skin lesions; however, as he was immunodeficient and had a long history of living in Vietnam, PMI was considered in the differential diagnosis. Bone marrow culture, which can detect P. marneffei even ten days after effective treatment, is reported to be the most sensitive test for PMI (1) . In our patient, bone marrow aspiration was not performed until day 11 of the fluconazole therapy, and P. marneffei was only detected from the bone marrow and not from the peripheral blood. The first-line therapy for PMI is liposomal amphotericin B followed by oral itraconazole, while fluconazole is recommended only for prophylaxis due to its weaker activity against PMI (3). In our case, the patient's esophageal candidiasis and cervical lymphadenopathy both improved with fluconazole, suggesting the possibility that the administration of fluconazole may be effective in the treatment of PMI.
In Japan, only ten cases of PMI have been reported to date (Table 2 ) (4-13). All patients had a history of traveling to Southeast Asia or India for at least one month and all were immunocompromised. Eight patients were HIV-positive and had low CD4 + cell counts (<100/mm 3 ), while two patients were HIV-negative but were receiving glucocorticoid therapy. In these cases, PMI was diagnosed by culture, polymerase chain reaction, histopathology, and cytology from various specimens (such as blood and skin biopsy specimens): our case was the only one that was diagnosed by bone marrow culture. The reported patients were treated with liposomal amphotericin B and/or itraconazole. With the exception of two patients, all of the patients were reported to have recovered: the data were missing for one case, while the other case of PMI died from the disease.
Although there are no established tests for the definitive serodiagnosis of PMI, circulating galactomannans may be an indicator of PMI (14) . Glucans are a major constituent of the cell walls of pathogenic fungi (with the exceptions of the Mucor, Rhizopus, Blastomyces dermatitidis, and Cryptococcus species) (15) . To our knowledge, there are several case reports that have noted the elevation of serum BDG levels in patients with PMI (5-7, 10, 11, 16-19) . Only eleven cases with increased BDG levels have been reported, and the number of PMI cases with normal serum BDG levels is not known. Among the cases in which the BDG levels were reported, the ratio of increased BDG levels was 82% (9/11). These findings suggest that PMI may cause serum BDG elevation -a finding which has not previously been reported. BDG is recognized as a useful serological marker of invasive fungal infections such as Aspergillus, Candida, and Pneumocystis (20, 21) . Serum BDG elevation may therefore be considered as an indicator of possible PMI in immunocompromised patients with a systemic illness and a history of an extended stay in South or Southeast Asia. Future studies with a larger number of cases are needed to determine the sensitivity and specificity of serum BDG elevation in the diagnosis of PMI because the number of cases in which the serum BDG levels were known in the present literature review was not sufficient.
In summary, PMI should be considered in the differential diagnosis of immunocompromised patients with a systemic illness and a history of travel to South and Southeast Asia. Furthermore, clinicians should consider serum BDG elevation as an indicator of possible PMI in these settings.
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